Table 3.
Percentage decrease in viability assessed by Calcein AM assay of adMSCs and bmMSCs treated with GNOs, GONRs and GONPs at concentration of 300 μg/ml at day 1 and 3 compared to control.
|
|
||||
|---|---|---|---|---|
| adMSC | bmMSC | |||
|
|
||||
| Day 1 | Day 3 | Day 1 | Day 3 | |
| GNOs | 98% | 38% | 19% | 21% |
| GONRs | 94% | 91% | 39% | 74% |
| GONPs | 65% | 80% | 62% | 74% |